Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab Induction in Crohn's Disease (UNITI-2)
NCT01369342Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2011
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of ustekinumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Jul 2011; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01369342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369342.